ARWR Arrowhead Pharmaceuticals Dashboard

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Company profile

Ticker

ARWR

Exchange

NASDAQ

Website

arrowheadpharma.com/

CEO

Christopher Anzalone

Incorporated

Delaware

Location

California

Fiscal year end

Sep 30

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC

SEC CIK

0000879407

Corporate docs

Articles of Incorporation & Bylaws

IRS number

460408024

ARWR stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Arrowhead Announces ARO-DUX4 As First Muscle Targeted RNAi Candidate Using TRiMTM Platform

15 Apr 21

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIMTM)

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

1 Mar 21

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s

The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts

11 Feb 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)

Stocks That Hit 52-Week Highs On Wednesday

10 Feb 21

B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $106

8 Feb 21

Press releases

Pro users get this 30m faster

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

16 Apr 21

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31,

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

15 Apr 21

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIMTM) platform.

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

1 Mar 21

Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

4 Feb 21

Arrowhead Pharmaceuticals, Inc. to Host Earnings Call

4 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

4 Feb 21

19 Apr 21

30 Sep 21

Financial summary

Financial statements Chart ARWR financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 20	Sep 19	Sep 18	Sep 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	139.92M	139.92M	139.92M	139.92M	139.92M	139.92M
Cash burn (monthly)	1.22M	26.76M	8.02M	9.36M	12.97M	9.23M
Cash used (since last report)	4.42M	96.86M	29.02M	33.89M	46.96M	33.42M
Cash remaining	135.5M	43.06M	110.9M	106.03M	92.96M	106.5M
Runway (months of cash)	111.0	1.6	13.8	11.3	7.2	11.5

Beta Read what these cash burn values mean

Recent insider trades

ARWR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Feb 21	Given Douglas B	Common Stock	Sell	Dispose S	Yes	No	88.73	1,125	99.82K	13,875
8 Feb 21	Patrick O'Brien	Common Stock	Sell	Dispose S	No	No	89.66	5,436	487.39K	293,375
8 Feb 21	Patrick O'Brien	Common Stock	Sell	Dispose S	No	No	88.88	45,348	4.03M	298,811
8 Feb 21	Patrick O'Brien	Common Stock	Sell	Dispose S	No	No	88.08	31,255	2.75M	344,159
8 Feb 21	Patrick O'Brien	Common Stock	Sell	Dispose S	No	No	86.72	7,961	690.38K	375,414
8 Feb 21	Patrick O'Brien	Common Stock	Option exercise	Aquire M	No	No	5.22	90,000	469.8K	383,375
8 Feb 21	Patrick O'Brien	Stock Option Common Stock	Option exercise	Dispose M	No	No	5.22	90,000	469.8K	60,000
15 Jan 21	Given Douglas B	Common Stock	Sell	Dispose S	Yes	No	83.28	3,000	249.84K	12,500
14 Jan 21	James C Hamilton	Common Stock	Sell	Dispose S	No	No	81.82	3,814	312.06K	126,250
14 Jan 21	James C Hamilton	Common Stock	Sell	Dispose S	No	No	80.97	6,186	500.88K	130,064

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ARWR institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

66.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	311	263	+18.3%
Opened positions	72	41	+75.6%
Closed positions	24	30	-20.0%
Increased positions	90	80	+12.5%
Reduced positions	110	95	+15.8%

13F shares	Current	Prev Q	Change
Total value	5.41B	2.9B	+86.6%
Total shares	69.39M	67.31M	+3.1%
Total puts	737K	631.9K	+16.6%
Total calls	1.33M	1.05M	+26.1%
Total put/call ratio	0.6	0.6	-7.5%

Largest owners	Shares	Value	Change
BLK Blackrock	12.56M	$963.97M	+0.0%
Vanguard	9.28M	$712.17M	+1.8%
STT State Street	3.93M	$301.7M	-13.5%
Johnson & Johnson Innovation - JJDC	3.26M	$250.21M	0.0%
IVZ Invesco	3.26M	$250.05M	-0.7%
JPM JPMorgan Chase & Co.	2.41M	$184.89M	+64.3%
Geode Capital Management	1.61M	$123.4M	+5.2%
NTRS Northern Trust	1.56M	$119.58M	-2.3%
CS Credit Suisse	1.51M	$116.17M	+3.3%
FMR	1.42M	$108.95M	-25.0%

Largest transactions	Shares	Bought/sold	Change
Point72 Asset Management	0	-1.33M	EXIT
Perceptive Advisors	1.07M	+1.07M	NEW
JPM JPMorgan Chase & Co.	2.41M	+943.01K	+64.3%
Norges Bank	858.78K	+858.78K	NEW
Western Financial	820.35K	+820.35K	NEW
STT State Street	3.93M	-611.11K	-13.5%
FMR	1.42M	-473.32K	-25.0%
First Light Asset Management	704.45K	+413.96K	+142.5%
Vivo Capital	205.09K	-371.41K	-64.4%
Farallon Capital Management	67.6K	-356K	-84.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Biocryst Pharmaceuticals • Alnylam Pharmaceuticals • Altimmune • Dicerna Pharmaceuticals • Arcturus Therapeutics • Viridian Therapeutics • Akcea Therapeutics • Exicure • Arcturus Therapeutics • 89bio

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: add, added, agency, AHA, arrangement, backed, cloud, computing, Customer, exacerbated, expansion, Finally, hosted, interim, lead, leader, line, maturity, mutual, Olpasiran, owed, Park, prepaid, profit, project, rare, Realized, reinvested, separately, Session, Software, strategy, structure, Subtopic, Takeda, toxicity, University, webinar, worsening

Removed: adaptive, advancement, advisory, aggregate, apparent, applying, approach, approval, assessed, base, begin, borrow, borrowing, carrying, classification, collateralized, collectively, critical, CTA, curative, deducting, determinable, determining, developing, diluted, discontinuation, discounted, dual, effect, efficacy, employed, entity, evaluate, excluded, executed, experience, expired, extend, FDA, filed, finance, greater, grown, histological, implicit, incremental, IND, index, industry, Jersey, leased, lessor, meet, merit, minimum, moved, NDA, nominated, obtain, obtaining, occasion, oral, ownership, package, pattern, permitted, pilot, pivotal, potentially, practical, prepare, public, reaching, readily, recognize, registration, requiring, response, Roche, scale, selected, serve, supported, typically, variation, vary, virtually, vivo, volume

From filing 10-Q 2021 Q1